RNAi leader Alnylam inks collaboration pact with startup; GV's Rosana Kapeller joins Schrödinger board
→ Eight months after putting together its $30 million A round, biotech startup CAMP4 has inked a new collaboration with RNAi trendsetter Alnylam. The two companies plan to work together to identify new drug targets for an undisclosed rare liver disease. CAMP4 CEO Josh Mandel-Brehm says his company will do the initial discovery work with Alnylam taking over any development work. The pact comes with an undisclosed upfront and milestones.
→ South San Francisco-based Rigel Pharmaceuticals just picked up a $30 million cash upfront from Spain’s Grifols for the European and Turkish commercial rights to their drug Tavalisse (fostamatinib disodium hexahydrate). The biotech is also in line for close to $300 million in regulatory and commercial milestones for the drug, including a $20 million hit on EU approval. The therapy is approved in the US for chronic immune thrombocytopenia.
→ New York-based Attune Pharmaceuticals has put together a $23 million B round intended to back their ongoing early-stage work on a new drug for HAE, or hereditary angioedema, a rare disease that causes erratic organ swelling. Venrock Healthcare Partners led the round, joined by LifeSci Venture Partners, RTW Investments, RA Capital, Boxer Capital and Tang Capital. RTW’s Rod Wong is joining the board.
→ New GV entrepreneur-in-residence Rosana Kapeller has joined the board at computational drug design expert Schrödinger. Kapeller, the former CSO at Nimbus, has extensive experience working with Schrödinger at her old gig.